AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we inform you that the Company has issued Duplicate share certificates in lieu of original share certificates
Buy Aarti Drugs; target of Rs 848: Anand Rathi
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 848 in its research report dated January 27, 2021. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith Q3FY21 Results Presentation of the Company for your records.
Earnings Call for Q3FY21 of Aarti Drugs
Conference Call with Aarti Drugs Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full earnings transcript. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith press release on the Financial Results for the quarter ended December 31, 2020. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for the Investors and Analysts has been scheduled on Wednesday, January 27, 2021 at 4:00 PM IST to discuss the Company's Q3 FY21 Results. Please find attached herewith invitation for the same. AARTI DRUGS LTD. - 524348 - Financial Results For The Quarter And Nine Months Ended December 31, 2020.
We wish to inform you that Board of Directors at its Meeting held on Monday, January 25, 2021, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2020. AARTI DRUGS LTD. - 524348 - Board Meeting Intimation for Audited Financial Results For The Quarter And Nine Months Ended December 31, 2020
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2021 ,inter alia, to consider and approve Audited Financial Results for the Quarter and Nine months ended December 31, 2020. AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates